HK40003985A - Dihydropyrimidinyl benzazepine carboxamide compounds - Google Patents

Description

Dihydropyrimidinylbenzazepine carboxamide compounds

Technical Field

The present application relates to novel dihydropyrimidinylbenzazepines having pharmaceutical activityCarboxamide compounds, processes for their preparation, pharmaceutical compositions containing them and their potential use as medicaments.

In particular, the present application relates to compounds, or pharmaceutically acceptable salts thereof, having the formula:

wherein X and R¹To R⁶As described below.

The compounds are TLR agonists. More specifically, the compounds are TLR8 agonists and are useful for the treatment and prevention (e.g., vaccination) of cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, transplant rejection, graft versus host disease, immunodeficiency, and infectious diseases.

Toll-like receptors (TLRs) are a family of transmembrane receptors which are expressed not only on immune system cells such as dendritic cells, macrophages, monocytes, T cells, B cells, NK cells and mast cells but also on a variety of non-immune cells such as endothelial cells, epithelial cells and even tumor cells (Kawai et al, Immunity,2011,34, 637-containing 650, Kawai et al, nat. Immunol.,2010,11, 373-384). TLRs which recognize bacterial and fungal components are expressed on the cell surface (i.e.TLR 1,2, 4,5 and 6), whereas other TLRs which recognize viral or microbial nucleic acids such as TLR3, 7, 8 and 9 are localized in the endolysosomal/phagosome compartment (Henessy et al, nat. Rev. drug Discovery 2010,9, 293-containing) and are mainly found by myeloid cells to be expressed in myeloid cells with specific activation sequences, and are restricted to the expression of IRkappa B and F-dependent protein receptor (TLR) receptor agonists such as TNF-activating protein receptor subtype I) in CD-expressing CD-19, CD-expressing chimeric protein receptor (I) and inducing expression of TNF-activating cytokines) in immune system cells such as CD-expressing TNF-19, CD-19, and the like, and CD-19, and CD-expressing a variety of proinflammatory cell expressing a variety of cytokines, and CD-expressing a variety of cytokines, and a variety of cytokines, which are also found to induce a variety of cytokines, and a variety of the myeloid cell expressing.

Small molecule agonists directed to TLR7 and TLR8 receptors and analogues modified for use as vaccine adjuvants or conjugates have been identified in a number of patents (i.e. WO1992015582, WO2007024612, WO2009111337, WO2010093436, WO2011017611, WO2011068233, WO2011139348, WO2012066336, WO2012167081, WO2013033345, WO2013166110 and US 2013202629). Clinical experience has been obtained mainly for TLR7 agonists, but only a few clinical studies have focused on the use of highly specific TLR8 agonists. So far the only FDA (food and drug administration in the United states)Office) approved small molecule drug is the TLR7 agonist imiquimod (ALDARA)^TM) As a topical medicament for the treatment of genital warts, superficial basal cell carcinoma and actinic keratosis. However, systemic administration of early TLR7 agonists such as resiquimod has been abandoned due to intolerable cardiotoxicity observed following therapeutic levels of global chemokine stimulation (Holldack, Drug Discovery Today,2013, 1-4). Knowledge of TLR8 agonists is posterior and is primarily limited to data for early mixed TLR7/8 agonists such as resiquimod. However, with regard to resiquimod agonists, the ability to stimulate TLR7 is superior compared to activation of TLR8, and thus most of the effects of resiquimod are dominated by the effects of TLR7 activity. Recently, VentiRX Pharmaceuticals (i.e. WO2007024612) has described TLR8 specific compounds such as VTX-2337, which for the first time allowed the analysis of the specific effects of TLR8 without simultaneous activation of TLR 7. There remains a need for small molecule TLR8 agonists and particularly those small molecule TLR8 agonists with improved potency or selectivity.

The present application relates to benzazepines having improved cellular potency compared to known TLR8 agonists of this typeCompounds for use in the treatment of cancer and preferably solid and lymphoma and for other uses including the treatment of certain skin conditions or diseases such as atopic dermatitis, the treatment of infectious diseases and preferably viral diseases and for use as an adjuvant in a vaccine formulated for cancer therapy or for desensitizing a receptor by continuous stimulation in the treatment of autoimmune diseases.

The novel compounds are characterized by improved cellular potency for TLR8 compared to known TLR8 agonists such as VTX-2337. In addition, these compounds are highly specific for TLR8, while having only low or even no activity for TLR 7. Since the expression pattern of TLR8 is more restricted, less severe side effects are expected when administered systemically and these compounds thus have advantageous properties compared to mixed TLR7/8 agonists.

Disclosure of Invention

The present application relates to benzazepines-4-carboxamide, or a pharmaceutically acceptable salt thereof, having the formula:

wherein

R¹Is C_3-7-an alkyl group;

R²is C_3-7-alkyl or C_3-7-cycloalkyl-C_1-7-an alkyl group;

R³is hydrogen or C_1-7-an alkyl group;

R⁴is hydrogen or C_1-7-an alkyl group;

R⁵selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-an alkoxy group;

R⁶selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-an alkoxy group;

x is N or CR⁷Wherein R is⁷Selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-alkoxy groups.

The application also relates to processes for preparing compounds of formula I.

The application also relates to pharmaceutical compositions comprising a compound of formula I as described above and a pharmaceutically acceptable carrier and/or adjuvant.

Another aspect of the present application is the use of compounds of formula I as therapeutically active substances for the treatment of diseases which can be mediated with TLR agonists and in particular TLR8 agonists. Thus, the application also relates to methods for treating diseases that can be mediated with TLR agonists, such as cancer and autoimmune or infectious diseases.

Detailed Description

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. In addition, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the present application.

Unless otherwise indicated, the nomenclature used herein is based on the IUPAC systematic nomenclature.

The term "compound of the present application" refers to compounds of formula I and solvates or salts (e.g., pharmaceutically acceptable salts) thereof.

The term "substituent" means an atom or group of atoms replacing a hydrogen atom on a parent molecule.

The term "lower alkyl" or "C", alone or in combination_1-7-alkyl "denotes a linear or branched, optionally substituted alkyl group having from 1 to 7 carbon atoms, in particular a linear or branched alkyl group having from 1 to 6 carbon atoms and more particularly a linear or branched alkyl group having from 1 to 4 carbon atoms. Straight and branched C_1-7Examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, the isomeric pentyl, hexyl and heptyl groups. Particularly preferred are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl.

The term "C_3-7Alkyl "likewise means a linear or branched alkyl group having 3 to 7 carbon atoms, as defined above. N-propyl is particularly preferred.

The term "C_3-7-cycloalkyl-C_1-7-alkyl "refers to lower alkyl as defined above, wherein at least one hydrogen atom of the lower alkyl is replaced by cycloalkyl. In cycloalkylalkyl radicals, particular mention is made ofOf interest is cyclopropylmethyl.

The term "cycloalkyl" or "C_3-7-cycloalkyl "denotes a saturated carbocyclic group containing from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, more particularly cyclopropyl.

The term "C_3-7-cycloalkyl-C_1-7-alkyl "refers to lower alkyl as defined above, wherein at least one hydrogen atom of the lower alkyl is replaced by cycloalkyl. Of cycloalkylalkyl, of particular interest is cyclopropylmethyl.

The term "halogen" refers to fluorine, chlorine, bromine and iodine, of which fluorine, chlorine and bromine are of particular interest. More specifically, halogen means fluorine or chlorine.

The term "lower alkoxy" or "C_1-7-alkoxy "refers to the group R '-O-, wherein R' is lower alkyl and the term" lower alkyl "has the previously given meaning. Examples of lower alkoxy are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, in particular methoxy.

The term "pharmaceutically acceptable" refers to the properties of a material that can be used to prepare a pharmaceutical composition, which is generally safe, non-toxic, and biologically or otherwise undesirable and acceptable for veterinary as well as human pharmaceutical use.

The compounds of formula I may form pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to those salts that retain the biological effectiveness and properties of the free base or free acid, which are not biologically or otherwise undesirable. Pharmaceutically acceptable salts include acid and base addition salts. For example, salts are acid addition salts of the compounds of formula I with physiologically compatible inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, sulfuric acid, sulfurous acid or phosphoric acid, or with organic acids such as methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, malonic acid, tartaric acid, benzoic acid, cinnamic acid, mandelic acid, pamoic acid, succinic acid or salicylic acid. In addition, pharmaceutically acceptable salts can be prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, zinc, copper, manganese, and aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of: primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, piperazine, N-ethylpiperidine, piperidine and polyamine resins. The compounds of formula I may also exist in zwitterionic form. Of particular interest are pharmaceutically acceptable salts of the compounds of formula I as sodium salts or salts with tertiary amines.

The compounds of formula I may also be solvated, e.g. hydrated. The solvation may be carried out during the preparation process or may occur, for example, as a result of the hygroscopic nature of the initially anhydrous compound of formula I (hydration). The term "pharmaceutically acceptable salts" also includes physiologically acceptable solvates.

The term "agonist" refers to a compound that enhances The activity of another compound or receptor site, as defined in Goodman and Gilman's "The Pharmacological Basis of Therapeutics,7th ed.", page35, Macmillan Publ, company, Canada, 1985. "full agonists" achieve full response, while "partial agonists" do not achieve full activation even when they occupy the entire receptor population. An "inverse agonist" produces the opposite effect of an agonist, but binds to the same receptor binding site.

The term "half maximal effective concentration" (EC)₅₀) Representing the plasma concentration of the particular compound required to achieve 50% of the maximum in vivo specific effect.

The term "therapeutically effective amount" means an amount of a compound of the present application which, when administered to a subject, (i) treats or prevents a particular disease, disorder, or condition; (ii) alleviating, ameliorating or eliminating one or more symptoms of a particular disease, disorder or condition; or (iii) preventing or delaying the onset of one or more symptoms of a particular disease, disorder, or condition described herein. The therapeutically effective amount will vary depending upon the compound, the disease state being treated, the severity of the disease being treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending physician or veterinarian, and other factors.

In particular, the present application relates to compounds, or pharmaceutically acceptable salts thereof, having the formula:

wherein

R¹Is C_3-7-an alkyl group;

R²is C_3-7-alkyl or C_3-7-cycloalkyl-C_1-7-an alkyl group;

R³is hydrogen or C_1-7-an alkyl group;

R⁴is hydrogen or C_1-7-an alkyl group;

R⁵selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-an alkoxy group;

R⁶selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-an alkoxy group;

x is N or CR⁷Wherein R is⁷Selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-alkoxy groups.

In one particular aspect, the application relates to compounds of formula I, wherein R¹Is n-propyl.

In another aspect, the application provides compounds of formula IIn which R is²Selected from n-propyl, isobutyl and cyclopropylmethyl. In particular, the application relates to compounds of formula I, wherein R¹And R²Is n-propyl.

In another aspect, the application relates to compounds of formula I as defined above, wherein R is³Is hydrogen or C_1-7Alkyl, in particular hydrogen or methyl. In another aspect, the application relates to compounds of formula I as defined above, wherein R is⁴Is hydrogen or C_1-7Alkyl, in particular hydrogen or methyl. More specifically, R³And R⁴Are all hydrogen. In another specific aspect, R³And R⁴Are all methyl.

In another aspect, the application provides compounds of formula I wherein X is CR⁷And R is⁷Selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-alkoxy groups. More specifically, R⁷Is hydrogen or halogen. Specifically, halogen is chlorine.

In another aspect, the application provides compounds of formula I, wherein X is N.

In another aspect, the application relates to compounds of formula I, wherein R⁵Selected from hydrogen, halogen and C_1-7-an alkyl group. More specifically, R⁵Is hydrogen, chlorine, fluorine or methyl.

In another aspect, the application provides compounds of formula I, wherein R⁶Selected from hydrogen, halogen and C_1-7-an alkyl group. More specifically, R⁶Is hydrogen, chlorine or methoxy.

Specific compounds of the present application are as follows:

2-amino-8- (1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (1, 4-dihydropyrido [3,4-d ]]Pyrimidin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-N- (cyclopropylmethyl) -8- (1, 4-dihydroquinazolin-2-yl) -N-propyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (1, 4-dihydroquinazolin-2-yl) -N-isobutyl-N-propyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (5-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (7-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (4, 4-dimethyl-1H-quinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (6-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (5-methyl-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (5-fluoro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide; and

2-amino-8- (6-methoxy-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide.

Another aspect of the present application is a process for the preparation of a compound of formula I as defined above, which comprises:

a) coupling a compound of formula II with a compound of formula III under basic conditions in the presence of a coupling agent,

the compound of formula II is:

wherein R is¹And R²As defined in claim 1 and PG is a protecting group,

the compound of formula III is:

wherein X and R³、R⁴、R⁵And R⁶As defined in claim 1 and PG₁Is a protective group, and is characterized in that,

and removing the protecting groups PG and PG under acidic conditions₁To give a compound of formula I:

wherein X and R¹To R⁶As defined in claim 1, the first and second,

and if desired, converting the resulting compound into a pharmaceutically acceptable salt.

It will be appreciated that the compounds of general formula I herein may be derivatized at functional groups to provide derivatives capable of conversion back to the parent compound in vivo. Physiologically acceptable and metabolically labile derivatives capable of producing the parent compound of formula I in vivo are also within the scope of the present application.

In particular, suitable protecting groups PG are amino protecting groups selected from Boc (tert-butoxycarbonyl), benzyl (Bz) and benzyloxycarbonyl (Cbz). Specifically, the protecting group is Boc.

By "removing the protecting group PG under acidic conditions" is meant that the protected compound is treated with an acid in a suitable solvent, for example, with trifluoroacetic acid (TFA) in a solvent such as Dichloromethane (DCM).

Suitable "coupling agents" for the reaction of the compound of formula II with the amine of formula III are selected from the group consisting of N, N '-Carbonyldiimidazole (CDI), N' -Dicyclohexylcarbodiimide (DCC), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 1- [ bis (dimethylamino) -methylene ] -1H-1,2, 3-triazolo [4,5-b ] pyridinium-3-oxide Hexafluorophosphate (HATU), 1-hydroxy-1, 2, 3-benzotriazole (HOBT), O-benzotriazole-N, N, N ', N' -tetramethyluronium Hexafluorophosphate (HBTU) or O-benzotriazole-1-yl-N, N, N ', N' -tetramethyluronium tetrafluoroborate (TBTU). Specifically, the coupling agent is TBTU. Suitable bases include triethylamine, N-methylmorpholine and in particular diisopropylethylamine.

By "under basic conditions" is meant the presence of a base and in particular a base selected from triethylamine, N-methylmorpholine and especially diisopropylethylamine. Typically, the reaction is carried out at room temperature in an inert solvent such as dimethylformamide or dichloromethane.

The present application also relates to compounds of formula I as defined above, obtainable according to the above process.

The compounds of the present application may be prepared by any conventional means. Methods suitable for synthesizing these compounds and their starting materials are provided in the schemes and examples below. Unless otherwise indicated, all substituents and in particular R¹To R⁴As defined above. Additionally and unless otherwise expressly stated, all reactions, reaction conditions, abbreviations and symbols have the meaning known to those of ordinary skill in organic chemistry.

A general synthetic route for preparing compounds of formula I is shown in scheme 1 below. A represents an aryl ring or heteroaryl ring.

Scheme 1

The compounds of formula I may be prepared according to scheme 1. The coupling reaction between carboxylic acid A and the selected amine IV gives an amide of formula V, which is then protected with an amino protecting group such as Boc to give a compound of formula VI. Hydrolysis of the compound of formula VI produces a carboxylic acid of formula II. The carboxylic acid of formula II is then coupled with the selected aryl or heteroaryl amine III to give the amide of formula VII. Finally, the compound of formula I is obtained by deprotection of an amino protecting group (e.g., Boc) and in situ cyclization of the amide of formula VII. In some cases, the compound of formula VII may contain additional acid-labile protecting groups derived from amine IV or amine III (e.g., Boc or TBS), which will also be removed in the final deprotection step.

A coupling agent (e.g., HBTU) is used to couple the carboxylic acid of formula a with the selected amine IV in the presence of a base (e.g., DIPEA) in a solvent (e.g., DCM) at ambient or elevated temperature to provide the compound of formula V.

The compound of formula V is then protected with an amino protecting group and specifically Boc to provide the compound of formula VI.

The compound of formula VI is dissolved in a suitable solvent (e.g., a mixed solvent such as THF/MeOH/H) at ambient or elevated temperature₂Hydrolysis with a base and in particular LiOH in O) gives the carboxylic acids of the formula II.

The carboxylic acid of formula II is then reacted with the selected aryl or heteroaryl amine of formula III in the presence of a base, specifically DIPEA, in a solvent, such as DCM, at ambient or elevated temperature with the aid of a suitable coupling agent, specifically HATU, to give the compound of formula VII.

Finally, the compound of formula I was obtained by treatment of the compound of formula VII with TFA in dichloromethane (Boc deprotection and in situ cyclization) and subsequent purification via preparative HPLC.

If one of the starting materials contains one or more functional Groups that are labile or reactive under the reaction conditions of one or more reaction steps, then the appropriate Protecting Group (PG) can be introduced prior to the critical step using methods known in the art (see, e.g., t.w. greene et al, Protective Groups in Organic Chemistry, John Wiley and sons inc. new York 1999, 3 rd edition). Such protecting groups can be removed at a later stage of the synthesis using standard methods known in the art. In addition to the Boc protecting group of amidines, the compounds of formula VII contain additional acid-labile protecting groups such as Boc or TBS from amine II, which will also be removed in this step.

If one or more compounds of the formula contain a chiral center, the compounds of the formula I can be obtained in the form of diastereomers or mixtures of enantiomers, which can be separated by methods known in the art, such as (chiral) HPLC or crystallization. The racemic compound can be separated into its enantiomers, for example, as follows: the enantiomers are separated by crystallization via diastereomeric salts or by specific chromatographic methods using chiral adsorbents or chiral eluents.

As mentioned above, the compounds of formula I herein are useful as medicaments for the treatment of diseases mediated by TLR agonists, and in particular for the treatment of diseases mediated by TLR8 agonists.

A compound as defined herein is a TLR8 receptor agonist in an in vitro cellular assay. Thus, the compounds of the present application are expected to be potentially useful agents for treating diseases or disorders that may benefit from activation of the immune system via TLR8 agonists. It can be used for treating or preventing diseases such as cancer, autoimmune diseases, inflammation, septicemia, allergy, asthma, transplant rejection, graft-versus-host disease, immunodeficiency and infectious diseases.

In more detail, the compounds of formula I of the present application are useful in oncology, i.e. they are useful in the treatment of common cancers including bladder, head and neck, prostate, colorectal, kidney, breast, lung, ovary, cervix, liver, pancreas, intestine and colon, stomach, thyroid, melanoma, skin and brain tumors and malignancies affecting the bone marrow such as leukemia and malignancies affecting the lymphoproliferative system such as hodgkin and non-hodgkin lymphomas; including the prevention (e.g., vaccination) and treatment of metastatic cancer and tumor recurrence and paraneoplastic syndromes.

The compounds of formula I of the present application are also useful for treating autoimmune diseases. An "autoimmune disease" is a disease or disorder caused by and directed against an individual's own tissue or organ or a co-segregation or manifestation thereof or a disorder caused thereby. An "autoimmune disease" can be an organ-specific disease (i.e., an immune response specific to an organ system such as the endocrine system, hematopoietic system, skin, cardiopulmonary system, gastrointestinal and hepatic systems, renal system, thyroid, ear, neuromuscular system, central nervous system, etc.) or a systemic disease that can affect multiple organ systems (e.g., Systemic Lupus Erythematosus (SLE), rheumatoid arthritis, polymyositis, etc.). In a particular aspect, the autoimmune disease is associated with skin, muscle tissue, and/or connective tissue.

Specific autoimmune diseases include autoimmune rheumatic diseases (e.g., rheumatoid arthritis, sjogren's syndrome, scleroderma, lupus such as SLE and lupus nephritis, polymyositis/dermatomyositis, cryoglobulinemia, antiphospholipid antibody syndrome and psoriatic arthritis), autoimmune gastrointestinal and liver disorders (e.g., inflammatory bowel disease, ulcerative colitis and crohn's disease, autoimmune gastritis and pernicious anemia, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis and celiac disease), vasculitis (e.g., ANCA negative vasculitis and ANCA-associated vasculitis including churg-schnei's vasculitis, wegener's granulomatosis and microscopic polyangiitis), autoimmune neurological disorders (e.g., multiple sclerosis, ocular clonus-myoclonus syndrome, myasthenia gravis, neuropathic ophthalmia, neuro, Parkinson's disease, Alzheimer's disease, and autoimmune polyneuropathy), renal disorders (e.g., glomerulonephritis, Goodpasture's syndrome, and Burger's disease), autoimmune skin disorders (e.g., psoriasis, rubella, urticaria, pemphigus vulgaris, bullous pemphigoid, and cutaneous lupus erythematosus), hematologic disorders (e.g., thrombocytopenic purpura, thrombotic thrombocytopenic purpura, post-transfusion purpura, and autoimmune hemolytic anemia), atherosclerosis, uveitis, autoimmune hearing disorders (e.g., inner ear disease and hearing loss), Behcet's disease, Raynaud's syndrome, organ transplantation, and autoimmune endocrine disorders (e.g., diabetes-related autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM), Addison's disease, and autoimmune thyroid diseases (e.g., Grave's disease and thyroiditis)), (e.g., Parkinson's disease, allergic diseases and responses, food allergies, drug allergies, insect allergies, rare allergic diseases such as mastocytosis, anaphylaxis, eczema (including allergic or atopic eczema), asthma such as bronchial asthma and autoimmune asthma, conditions involving bone marrow cell and T cell infiltration and chronic inflammatory responses.

The compounds of formula I of the present application are also useful in the treatment of infectious diseases. It is therefore useful for the treatment of viral diseases and in particular diseases caused by viral infections selected from: papillomaviruses such as Human Papillomaviruses (HPV) and those viruses that cause genital, common, and plantar warts, Herpes Simplex Virus (HSV), molluscum contagiosum, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), dengue virus, smallpox virus, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Varicella Zoster Virus (VZV), rhinoviruses, enteroviruses, adenoviruses, coronaviruses (e.g., SARS), influenza, mumps, and parainfluenza.

It can also be used for the treatment of bacterial diseases and in particular diseases caused by infection with a bacterium selected from the group consisting of mycobacteria, such as mycobacterium tuberculosis, mycobacterium avium and mycobacterium leprae. The compounds of formula I of the present application are also useful for the treatment of other infectious diseases such as chlamydia, fungal diseases and in particular fungal diseases selected from candidiasis, aspergillosis and cryptococcal meningitis, and parasitic diseases such as pneumocystis carinii pneumonia, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infections and leishmaniasis.

Thus, the expression "disease mediated by a TLR8 agonist" means a disease that can be treated by activating the immune system with a TLR8 agonist, such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, transplant rejection, graft versus host disease, immunodeficiency and infectious diseases. Specifically, the expression "diseases mediated by TLR agonists" means cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, transplant rejection, graft-versus-host disease, immunodeficiency, and infectious diseases.

In a particular aspect, the expression "disease mediated by a TLR8 agonist" relates to a cancer selected from the group consisting of: bladder cancer, head and neck cancer, liver cancer, prostate cancer, colorectal cancer, kidney cancer, breast cancer, lung cancer, ovarian cancer, cervical cancer, pancreatic cancer, intestinal and colon cancer, stomach cancer, thyroid cancer, melanoma, skin and brain tumors, and malignancies affecting the bone marrow such as leukemia and malignancies affecting the lymphoproliferative system such as hodgkin and non-hodgkin lymphoma; including the prevention (e.g., vaccination) and treatment of metastatic cancer and tumor recurrence and paraneoplastic syndromes.

The application also relates to pharmaceutical compositions comprising a compound of formula I as defined above and a pharmaceutically acceptable carrier and/or adjuvant. More specifically, the present application relates to pharmaceutical compositions useful for treating diseases mediated by TLR8 agonists.

In addition, the present application relates to compounds of formula I as defined above for use as therapeutically active substances and in particular as therapeutically active substances for the treatment of diseases mediated by TLR8 agonists. In particular, the present application relates to compounds of formula I for use in the treatment of cancer or autoimmune diseases or infectious diseases selected from viral diseases, bacterial diseases, fungal diseases and parasitic diseases.

In another aspect, the application relates to a method for treating a disease mediated by a TLR8 agonist, comprising administering to a human or animal a therapeutically active amount of a compound of formula I. In particular, the present application relates to methods for treating cancer and infectious diseases selected from viral diseases, bacterial diseases, fungal diseases and parasitic diseases.

The application also relates to the use of a compound of formula I as defined above for the treatment of diseases mediated by TLR8 agonists.

In addition, the application relates to the use of a compound of formula I as defined above for the manufacture of a medicament for the treatment of a disease mediated by a TLR8 agonist. In particular, the present application relates to the use of a compound of formula I as defined above for the preparation of a medicament for the treatment of cancer or an autoimmune disease or an infectious disease selected from the group consisting of viral diseases, bacterial diseases, fungal diseases and parasitic diseases.

In another aspect, the compounds of formula I may be combined with one or more additional therapeutic measures in a cancer treatment regimen.

In addition to administering a compound of the present application, combination therapy can include the adjunctive use of one or more agents that are effective in the treatment of cancer. Such measures include, but are not limited to, chemotherapeutic agents, immunotherapeutic agents, anti-angiogenic agents, cytokines, hormones, antibodies, polynucleotides, radiation, and photodynamic therapeutic agents. In a particular aspect, the combination therapy may be used to prevent cancer recurrence, inhibit metastasis, or inhibit the growth and/or spread of cancer or metastasis. As used herein, "in combination with … …" means that the compound of formula I is administered as part of a treatment regimen that includes one or more of the additional therapeutic measures described above. The present application therefore also relates to a method for the treatment of cancer, which comprises administering a therapeutically active amount of a compound of formula I in combination with one or more other pharmaceutically active compounds to a human being or animal.

The compounds of formula I may be used alone or in combination with one or more additional therapeutic measures for the treatment of autoimmune diseases.

In addition to administering a compound of the present application, combination therapy includes the adjunctive use of one or more measures that help to prevent or treat autoimmune diseases. Such measures include, but are not limited to, chemotherapeutic agents, immunotherapeutic agents, anti-angiogenic agents, cytokines, hormones, antibodies, polynucleotides, radiation, and photodynamic therapeutic agents. As used herein, "in combination with … …" means that the compound of formula I is administered as part of a treatment regimen that includes one or more of the additional therapeutic measures described above. The present application therefore also relates to a method for the treatment of autoimmune diseases, which comprises administering a therapeutically active amount of a compound of formula I in combination with one or more other pharmaceutically active compounds to a human being or animal.

In another aspect, the compounds of formula I may be used alone or in combination with one or more additional therapeutic measures for the treatment of infectious diseases.

In addition to administering a compound of the present application, combination therapy includes the adjunctive use of one or more measures that help to prevent or treat infectious diseases. Such measures include, but are not limited to, antiviral agents, antibiotics, and antifungal agents. As used herein, "in combination with … …" means that the compound of formula I is administered as part of a treatment regimen that includes one or more of the additional therapeutic measures described above. The present application therefore also relates to a method for the treatment of infectious diseases, which comprises administering a therapeutically active amount of a compound of formula I in combination with one or more other pharmaceutically active compounds to a human being or animal.

Pharmacological testing

The following tests were performed to determine the activity of the compounds of formula I:

HEK-Blue human TLR8 or TLR7 cells (Invivogen, San Diego, Calif., USA) were used for TLR8 and TLR7 Activity tests, respectively these cells were designed to study stimulation of human TLR8 or TLR7 by monitoring activation of NF-. kappa.B.SEAP (secretory embryonic alkaline phosphatase) reporter gene was placed under the control of IFN- β minimal promoter fused to five NF-. kappa.B and AP-1 binding sites.thus, expression of reporter protein was regulated by NF-. kappa.B promoter 20 hours after stimulation of human TLR8 or TLR 7. cell culture supernatant SEAP reporter Activity was determined using Quanti Blue kit (Invivogen, San Diego, Ca, USA) at 640nm wavelength, where the detection medium turned purple/Blue in the presence of alkaline phosphatase₅₀The value is obtained.

VTX-133 and VTX-135 are two examples described in international patent application WO2011/022509 and their activity in HEK-Blue human TLR7 and TLR8 cells is shown in table 1.

Notably, the novel compounds described herein have improved cellular potency at TLR8 compared to known TLR8 agonists such as VTX-133 and VTX-135 described in WO 2011022509. In addition, these compounds are highly specific for TLR8, but have no apparent activity on TLR 7. Thus, they are expected to have advantageous properties compared to mixed TLR7/8 agonists because the more restricted expression pattern of TLR8 causes less side effects when administered systemically.

The compounds of formula I have an activity (EC) in the above-described human TLR8 assay of 0.001 μ M to 0.03 μ M and more particularly 0.001 μ M to 0.015 μ M₅₀Value), and activity in the above-described human TLR7 assay (EC)₅₀Value) is greater than 100 μ M, which means that the compound shows very high selectivity for human TLR 8.

For example, the following compounds showed the following EC in the above assay₅₀The value:

TABLE 1

Examples	Human TLR8EC50[μM]	Human TLR7EC50[μM]
			VTX-133	0.077	1.86
VTX-135	0.039	3.61
			1	0.003	>100
2	0.003	>100
			3	0.006	>100
4	0.011	>100
			5	0.011	>100
6	0.009	>100
			7	0.007	>100
8	0.006	>100
			9	0.001	>100
10	0.003	>100
			11	0.002	>100

Pharmaceutical composition

The compounds of formula I and their pharmaceutically acceptable salts can be used as medicaments, for example in the form of pharmaceutical preparations for enteral, parenteral or topical administration. The compounds of formula I and their pharmaceutically acceptable salts may be administered systemically (e.g., parenterally) or locally (e.g., by local or intralesional injection). In some cases, the pharmaceutical formulation is administered topically, parenterally, orally, vaginally, intrauterine, intranasally, or by inhalation. As described herein, certain tissues may be preferred targets for TLR8 agonists. Thus, administration of TLR8 agonists to lymph nodes, spleen, bone marrow, blood, and tissues exposed to the virus is a preferred site of administration.

In one aspect, a pharmaceutical formulation comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, is administered parenterally. Parenteral routes of administration include, but are not limited to, transdermal, transmucosal, nasopharyngeal, pulmonary, and direct injection. Parenteral administration by injection may be by any parenteral injection route, including, but not limited to, Intravenous (IV) [ including bolus injection and infusion (e.g., rapid or slow) ], Intraperitoneal (IP), Intramuscular (IM), Subcutaneous (SC), and Intradermal (ID) routes. Transdermal and transmucosal administration can be performed, for example, by inclusion of a carrier (e.g., dimethyl sulfoxide, DMSO), application of electrical pulses (e.g., iontophoresis), or a combination thereof. Various devices that can be used for transdermal administration can be used. Formulations of the compounds of formula I suitable for parenteral administration are typically formulated in USP water or water for injection and may also contain pH buffers, salts, fillers, preservatives and other pharmaceutically acceptable excipients.

Transdermal administration is achieved by administering creams, lotions, gels, etc. that enable the TLR8 agonist to penetrate the skin and enter the bloodstream. Compositions suitable for transdermal administration include, but are not limited to, pharmaceutical suspensions, oils, creams and ointments applied directly to the skin or incorporated into a protective vehicle such as a transdermal device (so-called "patch"). Examples of suitable creams, ointments and the like can be found, for example, in the Physician's Desk Reference. Transdermal delivery can also be achieved by iontophoresis, for example using commercial patches that deliver their product continuously through unbroken skin over a period of days or longer. The use of this method allows the controlled delivery of the pharmaceutical composition in relatively large concentrations, allows the infusion of the combination drug and allows the simultaneous use of absorption enhancers. Administration by transdermal and transmucosal routes can be continuous or pulsatile.

Pulmonary administration is achieved by inhalation and includes delivery routes such as intranasal, transbronchial and transalveolar routes. The present application provides formulations of the compounds of formula I suitable for administration by inhalation, including but not limited to liquid suspensions for forming aerosols and powder forms for dry powder inhalation delivery systems. Devices suitable for administration by inhalation include, but are not limited to, nebulizers, vaporizers, nebulizers, and dry powder inhalation delivery devices. Other methods of delivery to the respiratory mucosa include delivery of liquid formulations, for example by nasal drops. Administration by inhalation is preferably accomplished in discrete doses (e.g., via a metered dose inhaler), although delivery similar to infusion can be achieved by use of a nebulizer.

The compounds of formula I and their pharmaceutically acceptable salts can also be administered orally, for example in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules.

The preparation of the pharmaceutical preparations can be carried out in a manner familiar to the person skilled in the art as follows: the compounds of the formula I and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, are brought into galenic administration forms together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, customary pharmaceutical auxiliaries.

Suitable support materials are not only inorganic support materials but also organic support materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient, however, no carrier may be required in the case of soft gelatine capsules). Suitable carrier materials for the preparation of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical formulations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

Conventional stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, taste-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants are considered as pharmaceutical adjuvants.

The dosage of the compounds of the formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration and will of course be matched to the individual requirements of each particular case. Daily doses of about 1 to 1000mg and especially about 1 to 300mg are contemplated for adult patients. Depending on the severity of the disease and the precise pharmacokinetic profile, the compounds may be administered in one or several daily dosage units, e.g. 1 to 3 dosage units.

Pharmaceutical preparations will generally contain from about 1 to 500mg and preferably from 1 to 100mg of a compound of formula I.

The following examples C1 through C3 illustrate exemplary compositions of the present application, but are merely representative thereof.

Example C1

Film-coated tablets containing the following ingredients can be prepared in a conventional manner:

the active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with an aqueous solution of polyvinylpyrrolidone. The granules were mixed with sodium starch glycolate and magnesium stearate and compressed to give cores weighing 120mg or 350mg respectively. The cores are coated with the above film-coated aqueous solution/suspension.

Example C2

Capsules containing the following ingredients can be prepared in a conventional manner:

the components were sieved and mixed and filled into size 2 capsules.

Example C3

The injection solution had the following composition:

the active ingredient is dissolved in a mixture of polyethylene glycol 400 and water for injection (part). The pH was adjusted to 5.0 by acetic acid. The volume was adjusted to 1.0ml by adding the remaining amount of water. The solution was filtered, filled into vials with the appropriate excess and sterilized.

The following examples serve to illustrate the present application in more detail. However, they are not intended to limit their scope in any way.

Examples

Abbreviations used in this application:

Boc₂o: di-tert-butyl dicarbonate; boc: tert-butyl carbamate; calc'd: calculating a value; CD (compact disc)₃OD: deuterated methanol; d: day; DIPEA: n, N-diisopropylethylamine; DCM: dichloromethane; DMAP: 4-dimethylaminopyridine; DMF-DMA: n, N-dimethylformamide dimethyl acetal; EA: ethyl acetate or EtOAc; EC (EC)₅₀: half the maximum effective concentration; h or hr: hours; HBTU: o- (benzotriazol-1-yl) -N, N' -tetramethyluronium hexafluorophosphate; DMAP: 4-dimethylaminopyridine; HATU: 1- [ bis (dimethylamino) methylene]-1H-1,2, 3-triazolo [4,5-b]Pyridinium 3-oxide hexafluorophosphate; HPLC-UV: high performance liquid chromatography with an ultraviolet detector; hz: hertz;mg: mg, MHz: megahertz, min: min, mL: mL, mM: mM, mM: mmol/L, mmol: millimole, MS: mass spectrometry, MW: molecular weight, NMR: nuclear magnetic resonance, PE: petroleum ether, prep-HPLC, preparative high performance liquid chromatography, rt: room temperature, sat: saturated, TBS: t-butyldimethylsilyl, sxt: hexameric peak, TEA: triethylamine, TFA: trifluoroacetic acid, THF: tetrahydrofuran, μ M: micromole/L, μ M: micron, UV: ultraviolet detector, OD: optical density, TLR 8: toll-like receptor 8, TLR 7: toll-like receptor 7, NF- κ B: nuclear factor-activated B cell κ light chain enhancer, SEAP: secreted embryonic alkaline phosphatase, IFN- β: interferon- β.

Example A: preparation of key intermediate A

2-amino-8-methoxycarbonyl-3H-1-benzazepine-4-carboxylic acid

A detailed synthetic route is provided in scheme 2.

a) Preparation of Compound B

To a solution of methyl 4-methyl-3-nitrobenzoate (100g,0.51mol) in DMF (1L) was added DMF-DMA (73g,0.61 mol). The reaction mixture was heated to 105 ℃ and held for 18 hours. The solvent was then removed in vacuo to give methyl 4- (2- (dimethylamino) vinyl) -3-nitrobenzoate (compound B,127g, crude) which was used in the next step without purification. MS calculated 251(M + H)⁺Measured value 251(M + H)⁺。

Scheme 2

b) Preparation of Compound C

To NaIO at 10 deg.C₄(327g,1.53mol)To a solution of methyl 4- (2- (dimethylamino) vinyl) -3-nitrobenzoate (compound B,127g,0.51mol) in THF (0.7L) was added a solution in a mixed solvent of THF (1.3L) and water (2.0L). After the reaction mixture was stirred at 25 ℃ for 18 hours, the mixture was filtered and then extracted with EA. The organic layer was washed with brine, over anhydrous Na₂SO₄Dried, filtered and concentrated to give the crude product. The crude product was purified by silica gel column chromatography (PE: EA ═ 20:1-10:1) to give methyl 4-formyl-3-nitrobenzoate (compound C,84g, 79%) as a yellow solid. MS calculated 210(M + H)⁺Measured value 210(M + H)⁺。

c) Preparation of Compound D

To a solution of tert-butyl 2- (triphenylphosphoranylidene) acetate (300g,0.797mol) in EA (2L) was added 2-bromoacetonitrile (57g,0.479mol) at 25 ℃. The reaction mixture was heated to reflux and held for 18 hours. After cooling to ambient temperature, the solid was filtered and the filtrate was concentrated. The residue was purified by trituration in EA and PE (200mL,2.5:1) to give the desired product tert-butyl 3-cyano-2- (triphenylphosphoranylidene) propionate (compound D,125g, 63%) as a white solid. MS calculated 416(M + H)⁺Measured value 416(M + H)⁺。

d) Preparation of Compound E

To a solution of methyl 4-formyl-3-nitrobenzoate (compound C,50g,0.24mol) in toluene (600mL) was added tert-butyl 3-cyano-2- (triphenylphosphoranylidene) propionate (compound D,109g,0.26mol) at 25 ℃. After the reaction mixture was stirred at 25 ℃ for 18 hours, it was cooled in an ice bath for 1 hour. The precipitate was collected and dried to give the desired product as a white solid. The filtrate was concentrated and treated with EtOH (120 mL). Insoluble material was filtered and the filtrate was concentrated to give another crop of desired product. The two batches were combined to give methyl 4- (3- (tert-butoxy) -2- (cyanomethyl) -3-oxoprop-1-en-1-yl) -3-nitrobenzoate (compound E,60g, 72%). MS calculated 347(M + H)⁺Measured value 347(M + H)⁺。

e) Preparation of Compound F

To a solution of methyl 4- (3- (tert-butoxy) -2- (cyanomethyl) -3-oxoprop-1-en-1-yl) -3-nitrobenzoate (compound E,30g,87mmol) in AcOH (450mL) was added Fe powder (29.1g,520mmol) at 60 ℃. After heating the reaction mixture at 85 ℃ for 3 hours, it was filtered through celite and the precipitate was washed with acetic acid. The filtrate was concentrated in vacuo and the residue was carefully washed with saturated NaHCO₃The aqueous solution (300mL) was basified. EA (600mL) was then added. The mixture was filtered through celite and the precipitate was washed with EA (200 mL). The filtrate was then washed with water and Na₂SO₄Drying and vacuum concentrating to obtain 2-amino-3H-benzo [ b ]]Aza derivatives4-tert-Butylester.8methyl-4, 8-dicarboxylate (Compound F,25g, 93%) as a pale yellow solid. MS calculated 317(M + H)⁺Measured value 317(M + H)⁺。

f) Preparation of Compound A

To 2-amino-3H-benzo [ b ] at 0 DEG C]Aza derivativesTo a solution of 4-tert-butyl-8-methyl (compound F,25g,80mmol) 4, 8-dicarboxylate in dioxane (400mL) was added a 1M HCl solution in dioxane (600 mL). After stirring the reaction mixture at 25 ℃ for 18H, it was concentrated in vacuo to give 2-amino-8- (methoxycarbonyl) -3H-benzo [ b]Aza derivatives-4-carboxylic acid hydrochloride (compound a,25g, crude) which was used in the next step without any purification. MS calculated 261(M + H)⁺Measured value 261(M + H)⁺。

Example B: preparation of key intermediate J

2- (tert-Butoxycarbonylamino) -4- (dipropylcarbamoyl) -3H-1-benzazepine-8-carboxylic acid

A detailed synthetic route is provided in scheme 3.

g) Preparation of Compound G

To 2-amino-8- (methoxycarbonyl) -3H-benzo [ b ] at 0 deg.C]Aza derivativesTo a mixture of-4-carboxylic acid hydrochloride (compound A,19g,64mmol), HBTU (29g,77mmol), DIPEA (33g,257mmol) in DMF (400mL) was added di-n-propylamine (13g,128 mmol). After the reaction mixture was stirred at 20 ℃ for 2 hours, it was washed with saturated NH₄Cl (500mL) and H₂O (1L) was diluted and extracted with EA (300 mL. times.3). The combined organic layers were washed with brine (300 mL. times.2) and Na₂SO₄Dried and concentrated to give the crude product. The crude product was purified by silica gel column chromatography (PE: EA ═ 1:1) to give 2-amino-4- (dipropylcarbamoyl) -3H-benzo [ b ═ b]Aza derivativesMethyl 8-carboxylate (compound G,18G, 82%) as a yellow solid. MS calculated 344(M + H)⁺Measured value 344(M + H)⁺。

Scheme 3

h) Preparation of Compound H

To 2-amino-4- (dipropylcarbamoyl) -3H-benzo [ b ] at 0 deg.C]Aza derivativesTo a mixture of methyl-8-carboxylate (Compound G,18G,53mmol) and TEA (16G,157mmol) in DCM (300mL) was added Boc₂O (17g,79 mmol). The mixture was stirred at 20 ℃ for 16 hoursWith saturated NH₄Cl (300mL) and H₂O (500mL) was diluted and extracted with DCM (100 mL. times.3). The combined organic layers were washed with brine (100 mL. times.2) and Na₂SO₄Dried and concentrated to give the crude product. The crude product was purified by silica gel column chromatography (PE: EA ═ 3:1) to give 2- ((tert-butoxycarbonyl) amino) -4- (dipropylcarbamoyl) -3H-benzo [ b ] b]Aza derivativesMethyl 8-carboxylate (Compound H,21g, yield: 91%) as a yellow solid. MS calculated 444(M + H)⁺Measured value 444(M + H)⁺。

i) Preparation of Compound J

To 2- ((tert-butoxycarbonyl) amino) -4- (dipropylcarbamoyl) -3H-benzo [ b ] at 0 deg.C]Aza derivatives-methyl 8-carboxylate (Compound H,5.0g,11.3mmol) in THF/H₂To the solution in O (1/1,100mL) was added an aqueous LiOH solution (1M,17mL,17 mmol). The mixture was then warmed to 25 ℃ and stirred for 6 hours. The mixture was poured into ice water (150mL), acidified to pH 5 with aqueous citric acid (5%) and extracted with EtOAc (100mL × 3). The combined organic layers were washed with brine (100 mL. times.2) and Na₂SO₄Drying and concentrating in vacuo to give 2- (tert-butoxycarbonylamino) -4- (dipropylcarbamoyl) -3H-1-benzazepine-8-carboxylic acid (compound J,4.0g, 83.3%) as yellow solid.¹H NMR(400MHz,DMSO-d₆) δ ppm is 7.78-7.72(m,1H),7.64(dd, J is 1.5,8.0Hz,1H),7.55(d, J is 8.3Hz,1H),6.93-6.89(m,1H),3.14(s,6H),1.54(br.s.,4H),1.44(s,9H),0.80(br.s., 6H). MS calculated value 430(M + H)⁺Measured value 430(M + H)⁺。

Example 1

2-amino-8- (1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

Example 1 can be prepared according to the general procedure of scheme 1. A detailed synthetic route is provided in scheme 4.

Scheme 4

Preparation of compound 1B:

to 2- (tert-butoxycarbonylamino) -4- (dipropylcarbamoyl) -3H-1-benzazepineTo a solution of (E) -8-carboxylic acid (Compound J,200mg,0.465mmol) in DMF (4.0mL) were added HATU (177mg,0.550mmol), DIPEA (84mg,0.60mmol) and N- [ (2-aminophenyl) methyl group]Tert-butyl carbamate (compound 1A,122mg,0.55 mmol). The solution was stirred at 50 ℃ for 24 hours. Water (10mL) was added and the mixture was extracted with EA (10 mL. times.2). The organic layer was washed with brine (10 mL. times.2) and Na₂SO₄Drying and vacuum drying gave the crude product. The residue was purified by preparative TLC to give N- [ [2- [ [2- (tert-butoxycarbonylamino) -4- (dipropylcarbamoyl) -3H-1-benzazepine-8-carbonyl]Amino group]Phenyl radical]Methyl radical]Tert-butyl carbamate (compound 1B,15mg) as a yellow solid. MS calculated 634(M + H)⁺Measured value 634(M + H)⁺。

Preparation of example 1:

to N- [ [2- [ [2- (tert-butoxycarbonylamino) -4- (dipropylcarbamoyl) -3H-1-benzazepine-8-carbonyl]Amino group]Phenyl radical]Methyl radical]To a solution of tert-butyl carbamate (compound 1B,15mg,0.023mmol) in DCM (1.0mL) was added TFA (0.3 mL). The reaction mixture was stirred at 20 ℃ for 2 hours. The reaction mixture was then concentrated and the residue was purified by preparative HPLC to give 2-amino-8- (1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide (example 1,12mg) as a yellow solid.¹H NMR (400MHz, MeOD) δ ppm 7.89-7.85(m,3H),7.42-7.36(m,2H),7.29-7.25(m,2H),7.16(s,1H),5.01(s,2H),3.48(m,4H),3.41(s,2H),1.74-1.69(m, 4H),1.00-0.93(m, 6H). MS calculated 416(M + H)⁺Measured value 416(M + H)⁺。

Example 2

2-amino-8- (1, 4-dihydropyrido [3,4-d ]]Pyrimidin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was prepared in analogy to example 1 using tert-butyl ((3-aminopyridin-4-yl) methyl) carbamate instead of tert-butyl 2-aminobenzylcarbamate. Example 2(16mg) was obtained as a yellow solid.¹H NMR(400MHz,MeOD)δppm＝8.44(m,2H) 7.84-7.80(m,3H),7.33-7.27(m,1H),7.01(s,1H),4.94(s,2H),3.41-3.16(m,6H),1.75-1.55(m.,4H),1.15-0.8(m, 6H). MS calculated 417(M + H)⁺Measured value 417(M + H)⁺。

Example 3

2-amino-N- (cyclopropylmethyl) -8- (1, 4-dihydroquinazolin-2-yl) -N-propyl-3H-1-benzazepine-4-carboxamides

A detailed synthetic route is provided in scheme 5.

Scheme 5

The title compound was synthesized in analogy to example 1 by using 2- ((tert-butoxycarbonyl) amino) -4- ((cyclopropylmethyl) (propyl) carbamoyl) -3H-benzo [ b-]Aza derivatives-8-Carboxylic acid (Compound 3A) instead of 2- (tert-Butoxycarbonylamino) -4- (dipropylcarbamoyl) -3H-1-benzazepine-8-carboxylic acid (compound J). Example 3(2mg) was obtained as a white solid.¹H NMR (400MHz, MeOD) δ ppm 7.87-7.85(m,3H),7.42-7.36(m,2H),7.30-7.24(m,2H),7.17(s,1H),5.04(s,2H),3.61-3.59(m,2H),3.44-3.41(m,4H),1.76-1.74(m,2H),1.31(br s,1H),1.11-0.97(br s,3H),0.64(br s,2H),0.31(br s, 2H). MS calculated 428(M + H)⁺Measured value 428 (M)+H)⁺。

Preparation of compound 3A:

the title compound was prepared in analogy to key intermediate J of example B by using N- (cyclopropylmethyl) propan-1-amine instead of di-N-propylamine.

Example 4

2-amino-8- (1, 4-dihydroquinazolin-2-yl) -N-isobutyl-N-propyl-3H-1-benzazepine-4-carboxamides

The title compound was prepared in analogy to example 3 by using 2-methyl-N-propylpropan-1-amine instead of N- (cyclopropylmethyl) propan-1-amine. Example 4(4.5mg) was obtained as a yellow solid.¹H NMR (400MHz, MeOD) δ ppm 7.87-7.83(m,3H),7.35-7.27(m,4H),7.14(s,1H),5.03(s,2H),3.38(br s,6H),1.75-1.6(m,3H),0.92(br s, 9H). MS calculated value 430(M + H)⁺Measured value 430(M + H)⁺。

Example 5

2-amino-8- (5-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was obtained by reactingReplacement of N- [ (2-aminophenyl) methyl group by tert-butyl 2-amino-6-chlorobenzylcarbamate (Compound 5C)]Tert-butyl carbamate. Example 5(19mg) was obtained as a white solid.¹H NMR (400MHz, MeOD) δ ppm 7.76-7.72(m,3H),7.79-7.78(m,2H),7.03(s,2H),4.92(s,2H),3.37(br s,6H),1.61-1.59(m, 4H),1.00-0.93(m, 6H). MS calculated 450(M + H)⁺Measured value 450(M + H)⁺。

The preparation of compound 5C is shown in scheme 6.

Scheme 6

To a solution of 2-chloro-6-nitrobenzonitrile (compound 5A,2.0g,10.98mmol) in THF (20mL) was added BH₃THF (33mL,32.9 mmol). The solution was refluxed for 3 hours. The reaction solution was cooled in an ice bath, and then MeOH (20mL) was added dropwise. The solution was stirred for 30 minutes, then Boc was added₂O (2.63g,12.1 mmol). The solution was stirred at 20 ℃ for 3 hours. The reaction solution was concentrated in vacuo and the residue was purified by column chromatography (PE/EtOAc. 20/1-5/1) to give crude tert-butyl 2-chloro-6-nitrobenzylcarbamate (compound 5B,1.4g, 44.5%) as a yellow oil which was used directly in the next step. MS calculated value 287(M + H)⁺Measurement value 287(M + H)⁺。

To a solution of tert-butyl 2-chloro-6-nitrobenzylcarbamate (compound 5B,1.4g,4.9mmol) in MeOH (70mL) was added NH₄Cl (3.6g,68.5mmol) and Zn (2.79g,44.0 mmol). The solution was stirred at 20 ℃ for 2 hours. The reaction solution was concentrated in vacuo. Water (30mL) was added and the mixture was extracted with EA (30 mL). The organic layer was washed with brine, over anhydrous Na₂SO₄Dried and concentrated in vacuo to give tert-butyl 2-amino-6-chlorobenzylcarbamate (compound 5C,800mg, 64%) as a yellow oil which was used directly in the next step. MS calculated 257(M + H)⁺Measured value 257(M + H)⁺。

Example 6

2-amino-8- (7-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was obtained in a similar manner to example 5 by using tert-butyl 2-amino-4-chlorobenzylcarbamate instead of N- [ (2-aminophenyl) methyl]Tert-butyl carbamate. Example 5(5mg) was obtained as a white solid.¹HNMR (400MHz, MeOD) δ ppm ═ 7.88-7.84(m,3H),7.35-7.28(m,3H),7.15(s,1H),5.01(s,2H),3.48-3.40(m,6H),1.75-1.68(m, 4H),0.96(br s, 6H). MS calculated 450(M + H)⁺Measured value 450(M + H)⁺。

Example 7

2-amino-8- (4, 4-dimethyl-1H-quinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was obtained in analogy to example 1 by using 2- (2-aminopropyl-2-yl) aniline instead of N- [ (2-aminophenyl) methyl]Tert-butyl carbamate. Example 7(18mg) was obtained as a white solid.¹H NMR (400MHz, MeOD) δ ppm 7.86(brs,3H),7.51-7.25(m,4H),7.17(s,1H),3.55-3.40(m,6H),1.86(s,6H),1.73-1.71(m,4H),0.97(br s, 6H). MS calculated 444(M + H)⁺Measured value of444(M+H)⁺。

Example 8

2-amino-8- (6-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was prepared in analogy to example 5 by using tert-butyl 2-amino-5-chlorobenzylcarbamate instead of tert-butyl 2-amino-6-chlorobenzylcarbamate. Example 8(6mg) was obtained as a white solid.¹H NMR (400MHz, MeOD) δ ppm 7.86-7.83(m,3H),7.42-7.23(m,3H),7.15(s,1H),5.02(s,2H),3.49-3.39(m,6H),1.74-1.69(m.,4H),1.00-0.92(br s, 6H). MS calculated 450(M + H)⁺Measured value 450(M + H)⁺。

Example 9

2-amino-8- (5-methyl-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was prepared in analogy to example 5 by using tert-butyl 2-amino-6-methylbenzylcarbamate instead of tert-butyl 2-amino-6-chlorobenzylcarbamate. Example 9(29mg) was obtained as a white solid.¹HNMR(400MHz,MeOD)δppm＝7.87-7.85(m,3H),7.30-7.28(m,1H),7.20-7.16(m,2H) 7.06-7.04(s,1H),4.99(s,2H),3.48(br s,4H),3.41(s,2H),2.30(s,3H),1.75-1.69(m.,4H),0.99-0.93(br s, 6H). MS calculated value 430(M + H)⁺Measured value 430(M + H)⁺。

Example 10

2-amino-8- (5-fluoro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was prepared in analogy to example 5 by using tert-butyl 2-amino-6-fluorobenzylcarbamate instead of tert-butyl 2-amino-6-chlorobenzylcarbamate. Example 10(5mg) was obtained as a white solid.¹H NMR (400MHz, MeOD) δ ppm 7.87-7.83(m,3H),7.46-7.40(m,1H),7.13-7.06(m,3H),5.03(s,2H),3.46-3.31(br s,4H),3.30(s,2H),1.72-1.67(m, 4H),0.98-0.97(br s, 6H). MS calculated value 434(M + H)⁺Measured value 434(M + H)⁺。

Example 11

2-amino-8- (6-methoxy-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamides

The title compound was obtained in analogy to example 5 by using tert-butyl 2-amino-5-methoxybenzylcarbamate instead of 2-ammonia6-chlorobenzyl carbamic acid tert-butyl ester. Example 11(37mg) was obtained as a white solid.¹H NMR (400MHz, MeOD) δ ppm 7.85-7.84(m,3H),7.21-7.15(m,2H),6.99-6.96(m,1H),6.87-6.86(m,1H),5.00(s,2H),3.85(s,3H),3.48(br s,4H),3.41(s,2H),2.30(s,3H),1.74-1.69(m.,4H),1.00-0.93(br s, 6H). MS calculated 446(M + H)⁺Measured value 446(M + H)⁺。

Claims (17)

1. BenzazepineA carboxamide compound or a pharmaceutically acceptable salt thereof, said compound having the formula:

wherein

R¹Is C_3-7-an alkyl group;

R²is C_3-7-alkyl or C_3-7-cycloalkyl-C_1-7-an alkyl group;

R³is hydrogen or C_1-7-an alkyl group;

R⁴is hydrogen or C_1-7-an alkyl group;

R⁵selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-an alkoxy group;

R⁶selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-an alkoxy group;

x is N or CR⁷Wherein R is⁷Selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-alkoxy groups.

2. The compound of claim 1, wherein R¹Is n-propyl.

3. The compound of claim 1 or 2, wherein R²Selected from n-propyl, isobutyl and cyclopropylmethyl.

4. A compound according to any one of claims 1 to 3, wherein R¹And R²Is n-propyl.

5. The compound of any one of claims 1 to 4, wherein R³And R⁴Is hydrogen.

6. The compound of any one of claims 1 to 4, wherein R³And R⁴Is methyl.

7. The compound of any one of claims 1 to 6, wherein X is CR⁷And R is⁷Selected from hydrogen, halogen, C_1-7-alkyl and C_1-7-alkoxy groups.

8. The compound of claim 7, wherein R⁷Is hydrogen or halogen.

9. The compound of any one of claims 1 to 6, wherein X is N.

10. The compound of any one of claims 1 to 9, wherein R⁵Selected from hydrogen, halogen and C_1-7-an alkyl group.

11. The compound of any one of claims 1 to 10, wherein R⁶Selected from hydrogen, halogen and C_1-7-alkoxy groups.

12. A compound of formula I according to claim 1, selected from:

2-amino-8- (1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (1, 4-dihydropyrido [3,4-d ]]Pyrimidin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-N- (cyclopropylmethyl) -8- (1, 4-dihydroquinazolin-2-yl) -N-propyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (1, 4-dihydroquinazolin-2-yl) -N-isobutyl-N-propyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (5-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (7-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (4, 4-dimethyl-1H-quinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (6-chloro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (5-methyl-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide;

2-amino-8- (5-fluoro-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide; and

2-amino-8- (6-methoxy-1, 4-dihydroquinazolin-2-yl) -N, N-dipropyl-3H-1-benzazepine-4-carboxamide.

13. A compound of formula I according to any one of claims 1 to 12 for use as a medicament.

14. A compound of formula I according to any one of claims 1 to 12 for use as a medicament for the treatment of diseases which can be mediated with TLR agonists.

15. A pharmaceutical composition comprising a compound of formula I according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier and/or adjuvant.

16. Use of a compound of formula I according to any one of claims 1 to 12 for the manufacture of a medicament for the treatment of a disease which can be mediated with a TLR agonist, in particular for the treatment of a disease selected from: cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, transplant rejection, graft versus host disease, immunodeficiency, and infectious diseases.

17. A process for the preparation of a compound of formula I as defined in claim 1, which comprises:

a) coupling a compound of formula II with a compound of formula III under basic conditions in the presence of a coupling agent,

the compound of formula II is:

wherein R is¹And R²As defined in claim 1 and PG is a protecting group,

the compound of formula III is:

wherein XAnd R³、R⁴、R⁵And R⁶As defined in claim 1 and PG₁Is a protective group, and is characterized in that,

and removing the protecting groups PG and PG under acidic conditions₁To give a compound of formula I:

wherein X and R¹To R⁶As defined in claim 1, the first and second,

and if desired, converting the resulting compound into a pharmaceutically acceptable salt.